Holen Sie sich die Stockscreener-App
1.2705
3.69%
0.0505
Schlusskurs vom Vortag:
$1.22
Offen:
$1.25
24-Stunden-Volumen:
23,536
Relative Volume:
0.14
Marktkapitalisierung:
$16.24M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-15.91M
KGV:
-0.8792
EPS:
-1.445
Netto-Cashflow:
$-15.07M
1W Leistung:
-15.67%
1M Leistung:
-38.89%
6M Leistung:
+12.95%
1J Leistung:
-71.60%
1-Tages-Spanne:
$1.18
$1.2705
1-Wochen-Bereich:
$1.16
$1.64
52-Wochen-Spanne:
$1.11
$4.7034
Lantern Pharma Inc Stock (LTRN) Company Profile
Firmenname
Lantern Pharma Inc
Sektor
Branche
Telefon
972-277-1136
Adresse
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
1.2705 | 15.60M | 0 | -15.91M | -15.07M | -1.445 |
VRTX
Vertex Pharmaceuticals Inc
|
524.29 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
766.56 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
190.04 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.58 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.39 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-10-07 | Eingeleitet | H.C. Wainwright | Buy |
Lantern Pharma Inc Aktie (LTRN) Neueste Nachrichten
Lantern Pharma Inc. (LTRN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Form 8K Lantern Pharma Inc For: 24 September By Investing.com - Investing.com Nigeria
Lantern Pharma hosts webinar on Open‑Medicine AI multi-agentic drug development platform - TradingView
Lantern Pharma Inc. (LTRN) Discusses Open-Medicine AI Platform Roadmap, Business Model, and Value Proposition for Therapeutic DevelopmentSlideshow (NASDAQ:LTRN) 2026-09-24 - Seeking Alpha
LTRN: Open Medicine AI expands its platform, targeting new diseases and broader adoption in drug development - TradingView
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET - BioSpace
Lantern Pharma Showcases Open-Medicine AI Growth Strategy - TipRanks
Form 8K Lantern Pharma Inc For: 23 September By Investing.com - Investing.com Nigeria
Lantern Pharma to present Open-Medicine AI roadmap, demo, commercial model in live webinar - TradingView
Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas - BioSpace
Lantern Pharma (LTRN) Secures Patent Allowance for Blood Cancer Treatment, Faces Valuation Challenges - GuruFocus
Lantern Pharma receives patent allowance for LP-284 cancer drug By Investing.com - Investing.com Canada
Lantern Pharma secures USPTO notice of allowance for LP-284 patent - TipRanks
Lantern Pharma receives patent allowance for LP-284 cancer drug - Investing.com
Lantern Pharma to host webinar on Open-Medicine AI - TipRanks
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global - Eagle-Tribune
Lantern Pharma Inc (NASDAQ: LTRN) Share Price, LTRN Stock News, LTRN Share Price & Updates - kalkine.ca
Lantern Pharma Q2 2026 Earnings Call: Complete Transcript - Benzinga
Lantern Pharma to Present Open-Medicine AI, a Multi-Agentic Platform for End-to-End Therapeutic Development, Business Model, Roadmap, and Value Proposition on September 23 - marketscreener.com
LTRN News | LANTERN PHARMA INC (NASDAQ:LTRN) - ChartMill
Lantern Pharma (NASDAQ: LTRN) to Host Webinar on Open-Medicine AI Platform, Business Model and Development Roadmap - Barchart.com
Lantern Pharma (LTRN) to Host Webinar Highlighting AI-Driven The - GuruFocus
Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23 - Yahoo Finance
Lantern Pharma Share PriceLTRN, RNS News, Articles, Quotes, & Charts (NASDAQ:LTRN) - Proactive financial news
Why Did LTRN Stock Surge 18% In Pre-Market Today? - Stocktwits
New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC) and FreeCast (NASDAQ:CAST) - guardonline.com
Lantern Pharma Inc. (LTRN) Stock Price & News - Syfe
Lantern Pharma Earnings Call: AI Spinout, Trial Momentum - TipRanks
Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript - AOL.com
Here's Why We're A Bit Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation - Sahm
Lantern Pharma Inc (LTRN) (Q2 2026) Earnings Call Highlights: AI - GuruFocus
Lantern Pharma Inc (LTRN) (Q2 2026) Earnings Call Highlights: AI-Driven Pipeline Advances Amid ... - Yahoo Finance
Lantern Pharma Inc (LTRN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lantern Pharma Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Lantern Pharma Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:LTRN) 2026-08-17 - Seeking Alpha
Lantern Pharma (LTRN) Slides 2.26% as Biotech Stock Approaches Critical $2.46 SupportKey Reversal Day - vinanet.vn
Lantern Pharma (LTRN) Updates Trial Design Amid Cash Raise; Mark - GuruFocus
Lantern Pharma (LTRN) Edges Up 0.76% to $2.65: Rangebound Trading Between Support and ResistanceBull Pennant - vinanet.vn
Form 8K Lantern Pharma Inc For: 14 August By Investing.com - Investing.com Nigeria
LTRN: Static price chart | Lantern Pharma Inc. | US51654W1018 - marketscreener.com
Lantern Pharma Reports 46.2% Wider Q2 2026 Loss at -$0.57/Share - AlphaStreet
Lantern Pharma Releases Q2 2026 Financial Results - AlphaStreet
Lantern Pharma (LTRN) Advances AI-Driven Oncology Pipeline Amid Valuation Challenges - GuruFocus
Lantern Q2 2026 slides: operating loss drops 25%, LP-300 data strengthens - Investing.com Canada
Lantern Pharma Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Lantern Pharma posts q2 2026 loss miss as stock slips - Investing.com Nigeria
Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update - 01net.it
LTRN: AI-driven clinical pipeline and Open-Medicine AI spin-out drive growth amid reduced expenses - TradingView
LTRN: Open-Medicine AI spinout and clinical advances drove a leaner Q2 with reduced operating loss - TradingView
Lantern Pharma Q2 2026 Earnings Call Transcript - MarketBeat
BRIEF-Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update - Dailyhunt
Finanzdaten der Lantern Pharma Inc-Aktie (LTRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lantern Pharma Inc-Aktie (LTRN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| KEYSER D JEFFREY | Director |
May 12 '26 |
Buy |
2.06 |
48,544 |
100,001 |
94,303 |
0.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):